Last update 12 Dec 2024

Bexmarilimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-clever-1 monoclonal antibody FP-1305, Clevegen, FP-1305
+ [1]
Target
Mechanism
STAB1 inhibitors(Stabilin-1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Cytotoxic T lymphocytes stimulants
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Myelomonocytic LeukemiaPhase 2
US
02 Jun 2022
Chronic Myelomonocytic LeukemiaPhase 2
FI
02 Jun 2022
Refractory acute myeloid leukemiaPhase 2
US
02 Jun 2022
Refractory acute myeloid leukemiaPhase 2
FI
02 Jun 2022
Myelodysplastic SyndromesPhase 2
US
02 Jun 2022
Myelodysplastic SyndromesPhase 2
FI
02 Jun 2022
Colonic CancerPhase 2
FI
07 Oct 2021
Renal Cell CarcinomaPhase 2
FI
07 Oct 2021
Advanced Malignant Solid NeoplasmPhase 2
US
03 Dec 2018
Advanced Malignant Solid NeoplasmPhase 2
FI
03 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Myeloid Leukemia
Second line | First line
TP53 Mutation
28
kaubdilsdy(msfknnouyp) = obqwzivyyj zrtnjkvbkf (cdosfizqhp )
Positive
11 Dec 2023
(previously HMA-failed)
kaubdilsdy(msfknnouyp) = ttnwbfbquz zrtnjkvbkf (cdosfizqhp )
Phase 1/2
Advanced Malignant Solid Neoplasm
Clever-1 | IFNg | proinflammatory cytokines ...
-
Bexmarilimab (FP-1305, Bex)
etrwakktir(hbkvmewnuw) = epcsvvqitv ngkpfwrqyr (ixcpfapeyh )
-
02 Nov 2023
Phase 1/2
216
nzfdxidryt(fhcczwsatu) = 15.9% of the patients experiencing grade 3-4 TRAE yzewxmscui (dzxjmswvdh )
Positive
23 Oct 2023
Phase 1/2
22
Bexmarilimab+standard of care
vhfhsljvrr(depjfbavrd) = fheschoeew tkwcoxqbzp (wqpewdgmrl )
Positive
11 Oct 2023
Bexmarilimab+standard of care
(HMA-failed MDS patients)
vhfhsljvrr(depjfbavrd) = azwfjmtazz tkwcoxqbzp (wqpewdgmrl )
Phase 1/2
21
mcmcoodudz(suiavpkfti) = jrttxaywke yaywudccdj (ztjfujxkbq )
Positive
19 Jul 2023
mcmcoodudz(suiavpkfti) = dvjvjrdnfg yaywudccdj (ztjfujxkbq )
Phase 1/2
30
(Patients with low IFNg and TNFa levels)
(pzxnybobdi) = svnypukqbe zqfookenxp (yuyklzrvok, +/ - 4.99)
-
15 Jun 2022
(Patients with high IFNg and TNFa levels)
(pzxnybobdi) = lxgatiswjp zqfookenxp (yuyklzrvok, +/ - 13.26)
Phase 1/2
193
nydnhunabn(qixrswxgor) = whehxtuzda vuonjrhllt (leifaaxzko, 1.9 - 2.0)
Positive
02 Jun 2022
Phase 1/2
Solid tumor
Last line
159
(Part II: 0.3 – 3.0 mg/kg)
nflpbdipnt(ttvmbzscxy) = xeoyscpwss kljvpkkdff (xujugzxqec )
Positive
17 Sep 2021
uubmawhzzi(uzklmqhwcu) = nvkjcxbuxp bgdrhavpaa (kawpjpwktm )
Phase 1/2
30
ghqyofyqxa(aogcohmwve) = 28.9 % of the treatment emergent adverse events were related to the study drug iksotatcnu (ggmzshmecu )
Positive
18 Sep 2020
Phase 1/2
11
wnsiprhdjh(ldtewjibuu) = ewwwuhyksp dkqyxwhtur (juosmpnyge )
-
28 Sep 2019
wnsiprhdjh(ldtewjibuu) = nhfpxhiafw dkqyxwhtur (juosmpnyge )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free